β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure-Reference-Cited by-同舟云学术

β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure

Published:2019-10-21 Issue:12 Volume:142 Page:3713-3727
ISSN:0006-8950
Container-title:Brain
language:en
Short-container-title:

Author:

Vanhaesebrouck An E¹,Webster Richard¹,Maxwell Susan¹,Rodriguez Cruz Pedro M¹²,Cossins Judith¹,Wickens James³,Liu Wei-wei¹,Cetin Hakan¹,Cheung Jonathan¹,Ramjattan Hayley⁴,Palace Jacqueline²,Beeson David¹^ORCID

Affiliation:

1. Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK

2. Department of Clinical Neurology, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK

3. Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, OX1 3TA, UK

4. Paediatric Neurology, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK

Abstract

The efficacy of anticholinesterase medication may diminish over time. Vanhaesebrouck et al. use an animal model of acetylcholine receptor deficiency syndrome to show that beta-2 adrenergic receptor agonists ameliorate the damage to neuromuscular junction structure caused by prolonged anticholinesterase medication, and thereby counteract the decline in efficacy.

Funder

Wellcome trust

MRC

Publisher

Oxford University Press (OUP)

Subject

Clinical Neurology

Link

http://academic.oup.com/brain/article-pdf/142/12/3713/31499540/awz322.pdf

Reference61 articles.

1. beta(2)-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS);Bartus;Neurobiol Dis,2016

2. Congenital myasthenic syndromes: recent advances;Beeson;Curr Opin Neurol,2016